May 23, 2022 by Chain Drug Review
Albert Bourla, BioNTech SE, Pfizer, Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age
Leading Headlines, Pharmacy
NEW YORK — Pfizer Inc. and BioNTech SE announced Monday topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to
April 26, 2021 by Chain Drug Review
Albert Bourla, COVID-19, COVID-19 vaccinations, Karen Lynch
April 26, 2021, News
NEW YORK — Now that more Americans are getting vaccinated in the race to build up enough herd immunity to beat the pandemic, questions are mounting as to how long the protection from those shots will last. Along with the unknown duration of immunity the shots offer, there’s also the worry of emerging variants that
November 9, 2020 by Chain Drug Review
Albert Bourla, BioNTech, COVID-19, COVID-19 vaccine, Pfizer
Leading Headlines, Pharmacy
NEW YORK — Pfizer announced on Monday that the vaccine the company jointly developed with BioNTech was 90% effective in preventing COVID-19 infections in ongoing Phase 3 trials. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of
July 11, 2018 by Chain Drug Review
Albert Bourla, Angela Hwang, biosimilars, Ian Read, John Young, Michael Goettler, Pfizer, Pfizer Consumer Healthcare
Business, Leading Headlines, Supplier News
NEW YORK — Pfizer Inc. announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These
October 11, 2017 by Chain Drug Review
Albert Bourla, Ian Read, Pfizer, Pfizer Consumer Healthcare, Pfizer Innovative Health
Business, Featured Articles, Leading Headlines, Pharmacy, Supplier News
NEW YORK — Pfizer Inc. is assessing strategic options for its Pfizer Consumer Healthcare subsidiary, including a potential sale. The pharmaceutical giant said this week that it’s considering “a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction.” However, the company noted that it may decided
August 22, 2016 by Chain Drug Review
Albert Bourla, David Hung, Ian Read, Medivation, oncology, Pfizer, Pfizer Innovative Health, XTANDI
Business, Pharmacy, Supplier News
NEW YORK — Boosting its oncology portfolio, Pfizer Inc. plans to acquire biopharmaceutical company Medivation for $14 billion in cash. Under the deal announced Monday, Pfizer is paying $81.50 a share in cash for San Francisco-based Medivation, whose products include XTANDI (enzalutamide), an androgen receptor inhibitor that the companies said is the nation’s leading novel